17-alpha-hydroxyprogesterone has been researched along with Carcinoma, Endometrioid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almås, B; Bertelsen, BE; Fasmer, KE; Forsse, D; Haldorsen, IS; Halle, MK; Krakstad, C; Tangen, IL; Trovik, J; Viste, K | 1 |
| Gama, R; Murphy, DJ; Salmons, N; Shearer, JL | 1 |
2 other study(ies) available for 17-alpha-hydroxyprogesterone and Carcinoma, Endometrioid
| Article | Year |
|---|---|
Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling.
Topics: 17-alpha-Hydroxyprogesterone; Androstenedione; Biomarkers, Tumor; Carcinoma, Endometrioid; Chromatography, Liquid; Cohort Studies; Cortodoxone; Endometrial Neoplasms; Estradiol; Estrogens; Estrone; Female; Gene Expression; Humans; Norway; RNA, Messenger; Signal Transduction; Tandem Mass Spectrometry | 2020 |
Postmenopausal hyperandrogenism: the under-recognized value of inhibins.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Glands; Aged; Androstenedione; Biomarkers, Tumor; Carcinoma, Endometrioid; Estradiol; Female; Gonadotropins; Humans; Hyperandrogenism; Inhibins; Ovarian Neoplasms; Postmenopause; Testosterone; Virilism | 2017 |